Thursday - May 22, 2025
Adjuvant PD-1 Blockade for Mismatch Repair-deficient Solid Cancers Directed by ctDNA Status Delivers Clinical Benefit
April 27, 2025
PHILADELPHIA, Pennsylvania, April 27 [Category: Medical] -- The American Association for Cancer Research posted the following news release:

* * *

Adjuvant PD-1 Blockade for Mismatch Repair-deficient Solid Cancers Directed by ctDNA Status Delivers Clinical Benefit

CHICAGO - Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products